Compromising between European and US allergen immunotherapy schools: Discussions from GUIMIT, the Mexican immunotherapy guidelines by Larenas Linnemann, Désirée et al.
Larenas-Linnemann et al. World Allergy Organization Journal (2020) 13:100444
http://doi.org/10.1016/j.waojou.2020.100444Compromising between European and US
allergen immunotherapy schools: Discussions
from GUIMIT, the Mexican immunotherapy
guidelines
Désirée Larenas-Linnemanna*E-mail: , Noel Rodríguez-Pérezb, Jorge A. Luna-Pechc,
Mónica Rodríguez-Gonzálezd, María Virginia Blandón-Vijila, Blanca E. Del-Río-Navarrof,
María del Carmen Costa-Domínguezd, Elsy Maureen Navarrete-Rodríguezf,
Carlos Macouzet-Sáncheze, José Antonio Ortega-Martellh, César Fireth Pozo-Beltráni,
Alan Estrada-Cardonag, Alfredo Arias-Cruze, Karen Guadalupe Rodríguez Galvánf,
Herson Brito-Díazj, María del Rosario Canseco-Raymundok, Enrique Emanuel Castelán-Chávezl,
Alberto José Escalante-Domínguezm, José Luis Gálvez-Romeron, Javier Gómez-Verao,
Sandra Nora González-Díaze, María Gracia Belinda Guerrero-Núñezp,
Dante Daniel Hernández-Colínq, Alejandra Macías-Weinmanne,
David Alejandro Mendoza-Hernándezr, Néstor Alejandro Meneses-Sánchezs,
María Dolores Mogica-Martínezt, Carol Vivian Moncayo-Coellou, Juan Manuel Montiel-Herrerav,
Patricia María O'Farril-Romanillosw, Ernesto Onuma-Takanex, Margarita Ortega-Cisnerosy,
Lorena Rangel-Garzaz, Héctor Stone-Aguilaraa, Carlos Torres-Lozanoab, Edna Venegas-Montoyaac,
Guillermo Wakida-Kusunokiad, Armando Partida-Gaytánae, Aída Inés López-Garcíaaf,
Ana Paola Macías-Roblesag, María de Jesús Ambriz-Morenoah, Amyra Ali Azamar-Jácomea,
Claudia Yusdivia Beltrán-De Pazw, Chrystopherson Caballero-Lópezaf,
Juan Carlos Fernández de Córdova-Aguirreai, José Roberto Fernández-Sotoaj,
José Santos Lozano-Sáenzz, José Joel Oyoqui-Floresz, Roberto Efrain Osorio-Escamillaz,
Fernando Ramírez-Jiménezak, Daniela Rivero-Yeverinoal, Eric Martínez Infanteam and
Miguel Alejandro Medina-ÁvalosanABSTRACT
Background: Allergen immunotherapy (AIT) has a longstanding history and still remains the only
disease-changing treatment for allergic rhinitis and asthma. Over the years 2 different schools have
developed their strategies: the United States (US) and the European. Allergen extracts available in
these regions are adapted to local practice. In other parts of the world, extracts from both regions
and local ones are commercialized, as in Mexico. Here, local experts developed a national AIT
guideline (GUIMIT 2019) searching for compromises between both schools.
Methods: Using ADAPTE methodology for transculturizing guidelines and AGREE-II for evalu-
ating guideline quality, GUIMIT selected 3 high-quality Main Reference Guidelines (MRGs): the
European Academy of Allergy, Asthma and Immunology (EAACI) guideines, the S2k guideline of
various German-speaking medical societies (2014), and the US Practice Parameters on Allergen
Immunotherapy 2011. We formulated clinical questions and based responses on the fused evi-
dence available in the MRGs, combined with local possibilities, patient's preference, and costs. We
came across several issues on which the MRGs disagreed. These are presented here along with
arguments of GUIMIT members to resolve them. GUIMIT (for a complete English version,
see Supplementary data) concluded the following:
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http://doi.org/10.1016/j.waojou.2020.100444Results: Related to the diagnosis of IgE-mediated respiratory allergy, apart from skin prick testing
complementary tests (challenges, in vitro testing and molecular such as species-specific allergens)
might be useful in selected cases to inform AIT composition. AIT is indicated in allergic rhinitis and
suggested in allergic asthma (once controlled) and IgE-mediated atopic dermatitis. Concerning
the correct subcutaneous AIT dose for compounding vials according to the US school: dosing
tables and formula are given; up to 4 non-related allergens can be mixed, refraining from mixing
high with low protease extracts. When using European extracts: the manufacturer's indications
should be followed; in multi-allergic patients 2 simultaneous injections can be given (100%
consensus); mixing is discouraged. In Mexico only allergoid tablets are available; based on doses
used in all sublingual immunotherapy (SLIT) publications referenced in MRGs, GUIMIT suggests a
probable effective dose related to subcutaneous immunotherapy (SCIT) might be: 50–200% of the
monthly SCIT dose given daily, maximum mixing 4 allergens. Also, a table with practical sug-
gestions on non-evidence-existing issues, developed with a simplified Delphi method, is added.
Finally, dissemination and implementation of guidelines is briefly discussed, explaining how we
used online tools for this in Mexico.
Conclusions: Countries where European and American AIT extracts are available should adjust
AIT according to which school is followed.
Keywords: Allergen immunotherapy, Guideline, Subcutaneous immunotherapy, Sublingual
immunotherapy, Allergen extractnowadays several fellows opt for completing theirBACKGROUND
Allergen immunotherapy (AIT) in Mexico has
been practiced since the pioneers of allergy star-
ted allergy departments The first department was
founded in the Hospital General in Mexico City in
1938 by Mario Salazar Mallén. The Hospital Gen-
eral had its own laboratory where allergen extracts
for skin testing and AIT were prepared. These first
Mexican allergists, from the 1930s to the 1970s,
received their allergy training in Europe (mainly
France), followed by a second wave (1960–1980)
of Mexican allergists trained in the United States
(US). Concurrently, from the middle of the twen-
tieth century onward, the allergy departments in
the main cities of Mexico have had training pro-
grams in allergy (and clinical immunology), andrresponding author. Médica Sur, Fundación clínica y hospital, Puente de
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ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).education with post-graduate courses and ex-
change programs in the United States or Europe
(ie, Spain, Germany). As such, historically and until
today allergology in Mexico has been influenced
by both the European and US schools.
Simultaneously, allergen extracts, available on
the Mexican market originate from manufacturers
from the United States, Europe, and local com-
panies. Consequently, AIT is practiced partly ac-
cording to the US method and partly according to
the European method; it is not rare to find the 2
techniques being practiced in 1 and the same al-
lergy office, selecting the most appropriate
method according to the sensitization and allergy
profile of the patient and his/her particular needs.Mexican guidelines on AIT and their renovation
Since the end of the past century, the first
Mexican consensus on AIT was published locally,1
and in 2011 the first official Mexican Guidelines on
allergy diagnosis and allergen immunotherapy
were developed by a considerable group of
national experts in the field.2 As an attempt was
made to follow the GRADE approach, classifying
Volume 13, No. 8, August 2020 3the quality of evidence article-per-article together
with several other factors, the methodological
rigor of these 2011 guidelines was considerable. In
a 2017 review, applying the AGREE-II instrument3
they still scored among the 3 highest ranking AIT
guidelines.4 However, by 2019 renovating the
Mexican AIT guideline seemed mandatory, as
new, high quality evidence was published in
original articles and comprehensive systematic
reviews, especially those of the European
Academy of Allergy, Asthma and Immunology
(EAACI), new AIT formulations were developed
with some of them launched on the Mexican
market, and some important chapters needed to
be added.Development and structure of GUIMIT 2019
The Guía Mexicana de Inmunoterapia (GUIMIT)
2019 was developed following the formal process
of the ADAPTE approach5 proposed by the
Guideines International Network (GIN), in which
few of the best-quality guidelines globally avail-
able on the subject6 are fused and transculturized
by local experts. For GUIMIT 2019 the 3 main
reference guidelines (MRG) were the AIT
guideline from the societies in the German-
speaking countries,7 the EAACI AIT guideline's,
sections on allergic rhinoconjunctivitis,8 venom
immunotherapy,9 and prevention10 and the third
update of the practice parameter on allergen
immunotherapy from the USA,11 see GUIMIT
2019 English version online (see Appendix A of
this article). The EAACI guideline on AIT for
asthma12 had not yet been published at that
moment. The authors of each chapter developed
clinical questions following the Patient-
Intervention-Comparator-Outcome (PICO) format
and sought the replies in the MRG. In the source
Table 1 the exact pages of the MRG with evidence
for the replies were tabulated. Then, in source
Table 2 the evidence was fused, and a proposed
recommendation for GUIMIT 2019 was
formulated (for links to all source documents
available in ResearchGate, see addendum 1
GUIMIT 2019-online). For some chapters, guid-
ance from the main reference guidelines was
missing and some chapter-specific reference
guidelines had to be added,13–19 following the
same selection strategy using AGREE-II to sort
out the best ones available.However, the main reference guidelines, some
reflecting the European school7,8,16 and some the
US school,11,15 did not agree on several issues as
the practice of AIT in both schools differs. When
this happened, a detailed analysis was made of
the exact wording in each reference guideline
and the source documents on which the
guidelines’ recommendations were based. These
elements were then discussed by the guideline
development group in the context of the Mexican
reality and local possibilities to finally emit a
strong or weak recommendation for GUIMIT
2019. We selected some of these clinical
questions and the discussion points around
them; they constitute the basis of the here
presented document. Our intention is not to
polarize between different views on AIT; on the
contrary, one of the main objectives of the this
manuscript is to explain the differences in
recommendations between both schools, as AIT
is practiced differently on both sides of the
ocean, and to make clear that both are valid
forms of AIT with the support of many decades
of experience behind them. Thus, as a starter, we
briefly present some historical perspectives of
both schools, before we proceed with the clinical
questions under discussion.European and US schools of AIT: historical
perspectives and first land-mark trials
The European school. After the first publication
by Noon in St. Mary's Hospital, London, 1911 on
the efficacy of AIT with a grass pollen (GP) extract
in enhancing the threshold of a conjunctival chal-
lenge in GP allergic patients out-of-season, his
colleague, Freeman, confirmed in a subsequent
publication the actual reduction of patients'
symptoms during the hay fever season.20 Four
decades later the first double-blind, placebo
controlled (DBPC) AIT trial by Frankland and
Augustin was conducted in 200 patients of the
same hospital. Frankland clearly describes the
placebo effect leading to a very good result in
almost a third of his placebo-group patients. Even
so, he was able to show a highly significant
symptom reduction in both active groups as
compared to placebo.21 The correct sample
calculation and the detailed description of
randomization, blinding, and drop-outs make this
study even today rated as moderately high
Clinical question (simplified wording) Delphi rounds results of GUIMIT experts'recommendations
Allergenic extracts based on mixtures with
homologous groups (i.e. tree mix, grass mix) can
be used in order to make the skin test less invasive.
 If they are positive, should AIT be prescribed
with such mixtures?
No (33% suggest no and 31% recommend no)
 If they are positive, should the clinician repeat
the skin test in order to break down allergens
from positive mixtures, to define which allergens
use in the AIT?
There is no consens s (28% recommend yes, 24%
suggest yes, 31% su gest no)
In a patient with skin tests positive to 5 non-
homologous pollens (¼ of different groups): Is it
cost-effective to ask for molecular diagnosis to
define the exact content of the proposed AIT?
Yes (37% recommen ed, 45% suggest)
In a patient with a high suspicion of house dust
mite allergy by clinical history, but a negative SPT:
is in vitro diagnosis with ImmunoCAP indicated?
Yes (30% recommen ed, 52% suggest)
Taking the precaution of keeping the effective
maintenance dose and not mixing high with low
proteases allergens: is SCIT with up to 4 allergens
mixed in a vial effective and safe?
Yes (37% recommen ed, 45% suggest)
(Dilution limits the n mber of allergens that can be
added to the mainte ance concentrate if a
therapeutic dose is be administered).
US AIT school: In a patient who does not
experience clinical improvement by one year of
SCIT: should the SCIT application be continued to
see if it improves during its 2 nd year of treatment?
No (29% recommen s no, 51% suggests no)
US AIT school: SCIT should be administered in a
single vial with each of the allergens at a fractional
dose (e.g. three allergens: each allergen one third
of the usual dose).
No (100% suggests)
100% recommends i cluding 100% of the
therapeutic doses o ach of the allergens included
European AIT school: Managing a patient allergic
to 2 non-homologous allergens with AIT,
 Should SCIT be administered as two injections
(one for each of the allergens) simultaneously,
with a 30 min post injection waiting period?
Yes (20% recommen s yes, 30% suggests yes, 15%
neutral)
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Volume 13, No. 8, August 2020 5scientific quality with low risk of bias.22 Two
decades later, extracts started to be
standardized, and by the end of the 1980s many
European extracts started to be alum-adsorbed,
aiming to enhance immunogenicity, reduce aller-
genicity, and obtain a depot effect that would
permit augmenting the dosing interval. A few
dose-finding trails were conducted with these
standardized alum-adsorbed subcutaneous AIT
extracts: first very small ones for house dust mite
(HDM),23–25 then a large, high-quality trial for
GP.26 As for the duration of AIT, at the turn of the
millennium Durham et al showed three years of
subcutaneous AIT with GP were enough.27 Since
then, many more trials have been conducted with
the sublingual route and some even in search of
the preventive effect of AIT.28
The US school. The use of skin testing, as
opposed to conjunctival testing from Noon and
Freeman, and new allergen extraction techniques
were first described by Cooke and Coca, respec-
tively. Both discoveries accelerated the develop-
ment of SCIT in the United States, which soon
became a widespread practice. The first allergy
clinic was founded by Cooke in New York. The first
DBPC, dose-finding trial with an allergen mix was
conducted by Johnstone and published with 4
years of treatment in 1961,29 and with up to 14
years in 1968, showing still reduced asthma
prevalence in the active group 1 year off-
treatment.30 Children with allergic asthma
received AIT with a mix of all allergens they
showed positivity to in skin testing, with 1 of 3
doses (1:107 v/v, 1:5000 or the highest tolerated
dose) or with saline placebo from the time they
came to the clinic until they turned 15 years of
age. The very low dose group behaved as the
placebo group, but for the other 2 active
treatment groups there was a clear dose-related,
statistically significant benefit in the sense of
reduction, or even annulation, of asthma attacks
and symptoms of exacerbation.30 Though
nowadays considered unethical, the blinding was
perfect as no patients knew they were part of a
trial. Thenceforth, the first dose-response efficacy
for a single allergen (ragweed) delivered in an
allergen mix was published by Lowell and Franklin
in 1965.31 They also showed the allergen
specificity of AIT,32 which was shortly thereafter
confirmed by Norman. Then, in 1997, the multi-
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http://doi.org/10.1016/j.waojou.2020.100444allergen subcutaneous AIT in asthma trial was
negative, probably due to poor allergen selec-
tion.33 Even so, it caused a strong set-back for AIT
in asthma until its final inclusion. Almost twenty
years later, in the Global Initiative for Asthma
(GINA)-algorithm (HDM sublingual AIT)34 and in
GINA 2020, both subcutaneous immunotherapy
(SCIT) and sublingual immunotherapy (SLIT) are
mentioned cautiously: " . potential benefits of
SCIT/SLIT must be weighed against the risk . "35
In conclusion, from the start, the focus of Euro-
pean AIT has been on the treatment of hay-fever
patients suffering from GP-allergy with grass pol-
len mono-AIT, first administered subcutaneously as
depot extracts, followed by sublingual AIT with
drops and more recently as sublingual tablets. In
Europe, a couple of studies have focused on birch
and other tree pollens. HDM AIT first received little
attention in small trials (n < 30 patients). It was not
until recently that HDM-sublingual AIT tablets have
been studied in large trials mainly in patients with
asthma.36 All this is in contrast to the initial US trials
almost all with mixes showing efficacy (with theBox 1. Clinical questions (1.1.3, 1.1.8, 1.2.4, 1.2.5)*
As compared to tests to determine specific
IgE in vitro in patients with suspected IgE-
mediated allergic disease: in vivo SPT should
be considered the first option to determine
IgE sensitization and to guide AIT?
We rec
In vitro
for mo
when S
In selected patients with allergic rhinitis or
conjunctivitis and/or asthma, in addition to
SPT, do specific nasal/conjunctival/bronchial
challenge tests (respectively) increase the
diagnostic accuracy for allergen selection to
guide AIT?
We sug
in terti
In patients with IgE-mediated allergy, both
children and adults, could molecular
diagnosis increase diagnostic accuracy and
thereby improve the accuracy of its
management?
We sug
In patients with IgE-mediated allergy, both
children and adults: are there species-
specific allergens for allergy diagnosis that
might guide the formulation of AIT? Mites,
trees, grass, weeds, molds, Hymenoptera,
epithelia?
We sug
* Numbers related to the questions in the original GUIMIT document, see onlin
development group.SPT ¼ skin prick testing, AIT ¼ Allergen immunotherapy, IgEexception of 1)33 of the extract-mix when evalu-
ated as a whole or when the efficacy of only 1
allergen within the mix was measured (ragweed).32
As a result, US allergists prepare AIT in their office
from concentrated stock vials that allow
maintaining the correct concentration of each
allergen even when mixed, while in Europe AIT is
more a final product meant to be administered as
such to the patient without manipulation. These 2
different schools of administering AIT persist
today as reflected in the US practice parameters
on immunotherapy,11 as opposed to the EAACI
AIT guidelines.10,12,37 Mexican allergists have
traditionally been influenced by both schools, and
in their practice have tried to take the best ideas
from both schools.
Clinical question and discussion I: Diagnosis of
IgE-mediated respiratory allergy: skin prick
testing and secondary allergy testing (challenges,
in vitro and molecular).
The first step for effective AIT is the correct selec-
tion of the causal allergen(s) for each patient.Response GUIMIT Agreement**
ommend: yes.
tests are complementary to SPT
st clinical scenarios (or first choice
PTs are contraindicated)
77%
gest: yes, as complementary tests
ary health care units
100%
gest: Yes, see text for indications 100%
gest: Yes for all options 100%
e file.** Percentage agreement among all members of the guideline
¼ immunoglobulin D
Volume 13, No. 8, August 2020 7Therefore, the first chapter in GUIMIT is dedicated
to the diagnosis of IgE-mediated allergy by in vivo
or in vitro testing. The latter has undergone
important development over the past decades in
Europe, while in the United States in vitro diag-
nosis is still not frequently used, and AIT is almost
exclusively based on SPT results. Our main refer-
ence guidelines do not dwell on diagnosis. As
such, here chapter-specific reference guidelines
had to be selected, using AGREE-II to evaluate
those with the highest quality.6
Skin prick testing (SPT) is still recommended as the
prime diagnostic resource to establish the allergen
selection for AIT, as until now no AIT trial has solely
been based on in vitro diagnostic testing. Howev-
er, GUIMIT experts have experienced poly-
sensitization profiles in many of their patients,
showing positivity for multiple allergens, not al-
ways of importance for the patient's symptoms.
Simultaneously, we recognize the importance of
restricting as much as possible the number of al-
lergens to be mixed in AIT, and as the clinical
history often does not allow to differentiate be-
tween sensitization and true allergy (see below),
additional tests might be needed after SPT to
define those allergens to be used for AIT. To this
end GUIMIT suggests the use of provocation tests
or in vitro testing. Although European colleagues
have defined details for organ-specific provoca-
tion tests in valuable position papers, this kind of
test is still seldom used in Mexico. Lately, in vitro
testing is slowly gaining ground. Looking at and
learning from our Spanish colleagues who also see
many polysensitized patients,38 Mexican allergists
are progressively realizing that molecular
diagnosis can help to differentiate between true
allergy versus SPT-positivity due to cross-
reactivity between related allergen families, or
due to the presence of pan-allergens. In conclu-
sion, GUIMIT stimulates the use of secondary
allergen testing to reduce the number of allergens
used in AIT as much as possible. A molecular
allergen table can be found in the document with
species-specific and cross-reacting allergen
molecules.Clinical question and discussion II: Can AIT be
prescribed in asthma or atopic dermatitis?
Although not all MRGs completely agree on the
details concerning AIT in asthmatic patients,evidence of its efficacy in allergic asthma is still
growing. As such, GUIMIT recommends adminis-
tering SCIT or SLIT in patients withmild ormoderate
controlled allergic asthma, because studies suggest
it reduces the risk of exacerbations and nonspecific
airway hyperresponsiveness. Moreover, GUIMIT
suggests to consider AIT in severe but controlled
allergic asthma, weighing risks against benefits,
preferably using administration schedules with a
higher safety profile and/or use of concomitant
treatment such as omalizumab. Administering AIT
even in patients with severe asthma, even though of
high-risk, is a quite common practice, as demon-
strated by a survey among members of the Amer-
ican Academy of Allergy Asthma and Immunology
(AAAAI) where 56% commented they have experi-
ence with administering SCIT in patients with severe
asthma.39Clinical question and discussion III: What is the
correct dosing for subcutaneous AIT?
As for atopic dermatitis, GUIMIT suggests AIT
might be a treatment option in extrinsic IgE-
mediated atopic dermatitis when there is a foun-
ded suspicion of clinically relevant allergen(s),
especially HDM. Here, evidence from randomized
clinical trials is starting to appear,40 and clinical
experience from GUIMIT members has been
positive.
In Mexico allergen extract vials are prescribed and
provided by the treating allergist. Various options
of allergen extracts exist on the Mexican market, as
registration rules are generally more flexible than
in Europe.41 Mexican allergists can buy
concentrated extracts to prepare AIT: 1) directly
imported by US manufacturers, 2) concentrated
extracts originated from US allergen distributors,
but accommodated by local Mexican
manufacturers, and 3) locally produced
concentrated extracts. Allergists can also buy
allergens and allergoids as end-products from
some European manufacturers licensed to sell in
Mexico. As such, the Mexican AIT guidelines have
to give guidance for both modalities of AIT. In
GUIMIT the subcutaneous AIT chapter is divided
into 2 parts: Chapter 4.2 related to practicing AIT
according to the US school and Chapter 4.3
reflecting AIT practiced according to the European
school.
Box 2. Clinical question (4.1.1, 4.3.4)*
Response
GUIMIT Agreement**
Is the efficacy and safety of SQ AIT dependent on reaching a
recommended therapeutic dose or – where appropriate – the maximum
tolerated dose?
We
recommend
yes
100%
US school: The interval between doses of immunotherapy is 15–30
days?
We
recommend:
YES
85%
European school: The interval between doses of immunotherapy is 4–6
weeks?
We
recommend:
YES
85%
* Numbers related to the questions in the original GUIMIT document, see online file.** Percentage agreement among all members of the guideline
development group.AIT ¼ Allergen immunotherapy, SQ ¼ standard quality
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http://doi.org/10.1016/j.waojou.2020.100444All main reference guidelines concur on the
globally agreed upon fact that the efficacy of AIT is
heavily dose dependent. Based on the US practice
parameters for AIT, GUIMIT experts have created
user-friendly dosing tables with calculations on
how to prepare AIT, taking the prescribed amount
of the concentrated vials to prepare the patient's
vial to obtain a correct projected maintenance
dose. This can only be accomplished diluting
concentrated vials and never using European ex-
tracts. In chapter 4.2 GUIMIT also gives further
preparation rules, such as not mixing extracts with
low and high protease content, to avoid allergen
degradation. Further, GUIMIT suggests not mixing
more than 4 non-homologous allergens, taken into
account cross-reactivity, see below. As AIT pre-
pared from concentrated vials has natural aller-
gens and no depot adjuvants, the administration
frequency recommended is once to twice monthly.
Both reference guidelines developed in Europe do
not go into detail in relation to allergen dose, as
the European allergen manufacturers produce
end-products that should be administered as such
to the patients without manipulation. Some Euro-
pean allergen extracts available in Mexico are
depot preparations of allergoids (Inmunotek),
that can be used for rush or cluster schedules and
that allow administration every 4–6 weeks during
maintenance. The pre-seasonal or pre-co-seasonal
schedules used in certain parts of Europe are
hardly useful in Mexico, where generally pollina-
tion is almost year-round.
The subcutaneous AIT chapter ends with general-
ized recommendations on how to enhance AITsafety. This starts with the identification of the cor-
rect vial and dose: GUIMIT recommends having 2
patient-identifiers on each vial and vial identifica-
tion by 2 persons, the personnel administering and
the patient. Also, there is a pre-administration
questionnaire integrated into the manuscript, and
taking vital signs, including a peak-flow measure-
ment, is suggested. In case of detecting any risk
factor present at the moment of AIT administration
the dose can be reduced (especially when using
native allergens, a suggested dose-adjustment ta-
ble is incorporated) or postponed.
Clinical question and discussion IV: What is the
correct dosing for sublingual AIT?
Similarly, for SLIT there are several different prod-
ucts available in Mexico. Some European manu-
facturers are licensed to sell their liquid products
(ALK-Abelló, IPI-ASAC, Inmunotek), and there is 1
option for allergoid SLIT tablets (Lofarma). Then,
there is the option to prepare liquid SLIT products
out of concentrated allergen vials, just as in SCIT.
Internationally, this has been more controversial,
as some experts argue that a clearly defined
maintenance dose for tablet SLIT does not exist,
and each product has to show its own efficacy and
safety, because in tablet SLIT these do not depend
only on the amount of allergen but also the
vehicle.42
However, in Mexico two issues arise when using
European end-products for SLIT. Firstly, SLIT with
well-studied tablets is not available in Mexico.
Secondly, more than 80% of Mexican patients are
poly-sensitized,43 and when a careful clinical
Box 3. Clinical questions (5.1.1–5.1.4)*
Response GUIMIT Agreement**
For products, specifically sold for SLIT: Is there a probable
effective maintenance dose?
We recommend: yes 100%
What is this probable effective SLIT maintenance dose? We suggest 5-50mcg major
allergen daily
100%
For liquid SLIT products, prepared from vials with
concentrate allergenic extract: Is there a probable
effective maintenance dose, relative to the SCIT dose?
We suggest: yes 100%
For natural allergen extracts: what will this daily
maintenance dose be, in relation to SCIT?
We suggest 50–200% of the
monthly dose of SCIT
100%
* Number related to the question in the original GUIMIT document, see online file.** Percentage agreement among all members of the guideline development
group.SCIT ¼ subcutaneous allergen immunotherapy; SLIT ¼ sublingual allergen immunotherapy.
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dual- and most even poly-allergic. Hence, mono-
allergen SLIT shall only partly cover their prob-
lem. European-product-based SLIT is costly and
using 2 or more European SLIT products simulta-
neously might be unaffordable for many patients.
In preparing liquid SLIT some allergens could be
mixed together. Also, some US investigators have
shown that effective liquid grass-pollen and HDM
SLIT can be made from concentrated US allergen
vials.44,45 Thus, following previous SLIT-dosing
discussions, GUIMIT experts studied SLIT doses
used in high-quality clinical trials integrated in
recently conducted EAACI systematic reviews and
metanalyses.28,46,47 These are presented in a table
in the GUIMIT document. Thus, it became clear the
majority of effective SLIT trials used a daily dose of
50–200% of the related monthly SCIT dose. As
pauci-allergen liquid SLIT is actually practiced by
many Mexican allergists, GUIMIT gives some
dosing suggestions for this kind of practice, based
on the above-mentioned analyses. Since the Amar
trial showed 10-allergen SLIT is ineffective,44
GUIMIT suggests not to mix more than 4 non-
homologous allergens, see below.
Clinical question and discussion V: Mono- versus
multi-allergen AIT in multi-allergic patients
AIT is allergen-specific,32,48,49 and Wagenmann
et al elegantly demonstrated in dual birch-grass
allergic patients, giving mono-allergen AIT to half
of them with birch and to half of them with grass
pollen that AIT only improves symptoms whenexposed to the allergen included in the AIT, but
not when exposed to the non-targeted
allergen.49,50
Pollination in large parts of our country continues
all year long and pollen seasons heavily overlap,
making it difficult to define the causal pollen
allergen in a poly-sensitized patient, based on
anamnesis. Also, humidity in the whole of Mexico
is high, facilitating HDM growth and HDM sensiti-
zation in Mexican allergic rhinitis patients varies
between 45% and 89%.43 Finally, national customs
favor close contact with pets. As a result the vast
majority of allergic patients has perennial
symptoms—be it some with seasonal
exacerbations51—caused by poly-allergy. In such
a scenario, mono-allergen AIT might be insufficient
for most.
Our MRGs disagree between one another on the
use of allergen mixes in SCIT, with the European
guidelines only allowing mixing under specific
circumstances and preferentially only between
homologous allergens while in the United States
mixing allergens is common practice. With the
progression of knowledge on the exact composi-
tion of allergens we now know that even in mono-
allergen AIT the patient is exposed to multiple
major allergen molecules, especially in HDM
AIT.52,53 Mixing a few non-homologous allergens
together would only partly augment the number of
allergenic proteins. As for now, the maximum
number of allergenic proteins a patient can react
to is not known, but it is very probable pauci-
allergen AIT is within the acceptable range. As
Box 4. Clinical questions (4.a.4a-d, 4.3.6, 4.3.7)*
Response GUIMIT Agreement**
US school (SCIT or SLIT)
Is it advisable to mix taxonomically
unrelated allergens?
We recommend: YES CAVE: protease content, see
below
100%
How many allergens could be
mixed in one vial?
We recommend: consider dilutional effect, see
below
100%
Which allergens to mix and which
not to mix
We recommend: Do not mix allergens with high
protease content with low-protease content
allergens
100%
Can standardized allergens be
mixed with non-standardized
ones?
We recommend: YES 100%
European school
Can mixtures be made with
unrelated allergens?
We suggest: No 100%
How many allergens could be
mixed in one vial?
We recommend: No, eventually 2 100%
* Numbers related to the questions in the original GUIMIT document, see online file.** Percentage agreement among all members of the guideline
development group.SCIT ¼ subcutaneous allergen immunotherapy; SLIT ¼ sublingual allergen immunotherapy.
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almost all initial SCIT trials with mixes in the United
States showed efficacy.
The same holds true for allergen mixes for SLIT
with Japanese19 guidelines favoring this option,
the World Allergy Organization guidelines18
stating it is safe, and the European guidelines
opposing. Evidence from clinical trials shows dual
allergen liquid SLIT is effective and safe,45,54,55
but 10-allergen liquid SLIT is not effective44.
Thus, compromising between the different
schools, GUIMIT experts suggest for AIT prepared
from concentrated vials—per the US school—a
maximum of 4 non-homologous allergens can be
mixed in one vial, both for SCIT and for SLIT. To
reduce the allergens administered as much as
possible, cross-reactivity should be taken into ac-
count when selecting the AIT-allergens and sec-
ondary IgE-mediated allergy tests are suggested
(see discussion point).
Based on the European reference guidelines,
GUIMIT suggests for the treatment of multi-allergic
patients with AIT using European extracts to select
the 2 most important allergens and to administer
them in 2 separate shots during each AIT session.A Delphi consensus among the GUIMIT experts
defined that both shots can be given simulta-
neously, based on long-term experience with such
practice among Mexican allergists.Practical issues related to AIT on which no
evidence exists
While developing GUIMIT, experts came across
several practical points of importance in AIT daily
practice, but without any clear evidence. These
clinical questions were submitted to a simplified
Delphi round, to obtain the anonymous, unbiased
opinion of the 52 GUIMIT experts. Their responses
led to a consensus as to whether the proposed
actions should be recommended, suggested, or
recommended or suggested against. The results
are presented in GUIMIT as "suggestions for good
clinical practice" at the end of each chapter's evi-
dence table. Some are presented here in Table 1.
GUIMIT further included chapters on the
mechanisms of AIT, Hymenoptera allergy, allergen
extracts, safety and adverse event treatment with
AIT, and the future of AIT. These are not presented
here but can be reviewed in the online GUIMIT file.
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US, and Mexican guidelines on AIT
Guidelines generally have good dissemination
strategies, as they are developed in close coop-
eration with specialty-specific organizations; thus
ample visibility is given during annual congresses,
courses, and in specialty-specific journals. The
EAACI guideline especially has been disseminated
extensively, as well as strategies for its imple-
mentation,56 also paying attention to the
availability of high quality allergen extracts in
Europe.57 Even so, reluctancy for change is
inherent to the human being. Thus, an important
focus group for guidelines should be the young
fellows. For GUIMIT we used the following
dissemination strategies.
1. Pre-launch: An online survey (SurveyMonkey)
was conducted among all members of both the
Colegio Mexicano de Inmunología Clínica y
Alergia (CMICA) and the Colegio Mexicano de
Pediatras Especialistas in Inmunología Clínica y
Alergia (COMPEDIA). This serves both as
expectation and pre-promotion of what is going
to come, and it shows the guideline develop-
ment group which issues to focus on for
possible improvement. One survey has already
been published.58
2. The GUIMIT launch had a major place during
both national allergy congresses in 2019. Dur-
ing the CMICA congress, the guideline was
distributed physically among all attendees.
3. GUIMIT was published as a supplement freely
downloadable in Revista Alergia México, a
PubMed indexed journal in Spanish. Since its
launch, 3654 downloads have been registered,
suggesting diffusion beyond Mexican boarders.
GUIMIT served as an important support to col-
leagues in South American countries in negoti-
ating with regulatory authorities in their
countries (personal communication).
4. In the fall, COMPEDIA, held Sunday schools:
one dedicated to GUIMIT with ample discussion
among live and online attendees.
5. Chapter-chairs were recorded presenting core
points of their chapters. This has just been made
freely accessible on CMICA TV.6. All program directors were invited to participate
in the development group of GUIMIT. The
guideline is part of the curriculum they teach to
their students (in several places together with
the North American and European guidelines).
7. Finally, and very importantly: Consejo Mexicano
de Inmunología Clínica y Alergia, the body that
certifies allergists in Mexico, recognizes GUIMIT,
and several board exam questions are related to
it. GUIMIT is a reference document for the stu-
dents as could be confirmed during their final
exam (personal communication).
However, evidence shows the main difficulty
guidelines still face is the gap between their con-
tent and their application in daily patient care. For
the US guideline, a survey was conducted asking
members of the AAAAI and the American College
of Allergy Asthma and Immunology (ACAAI) about
their dosing: only 57%–65% of the standardized
extract maintenance dosing fell within the dose
range, recommended in the Practice Parame-
ters.59 In another survey, 58% (629/1085)
commented to have given AIT to severe
asthmatic patients, even though this is a
contraindication according to the US guideline,39
only to give some examples.DISCUSSION
We presented here how Mexican allergists have
developed their AIT guidelines, constructing a
document following the ADAPTE approach based
on the evidence from high-quality AIT guidelines
from several regions, mainly Europe and the
United States, with sometimes conflicting strate-
gies. We showed how European and US views
were fused into a harmonized presentation,
adopting some new techniques more favored in
Europe (challenge testing, in vitro and molecular
diagnosis), but also more flexible forms of pre-
paring AIT as done in the United States. Then we
demonstrated how we formulated some
consensus suggestions of good clinical practice on
issues with lacking evidence.
Something similar is done yearly by colleagues
from Europe in workshops discussing the "Future of
the Allergists and Specific Immunotherapy" (FASIT),
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comprehension between forms of allergen extracts
and AIT as practiced in Europe and North America
seemed also to be the objective of Mahler et al in a
recent CME article,61 though their presentation
might have been better balanced.62
The mono-multi allergen AIT discussion shall
continue to be an ever-returning issue, as Euro-
pean colleagues are correct that no recent well-
designed trial exists showing multi-allergen mixes
work. Most probably no such trial shall ever see the
light again, due to financial and ethical reasons.
On the other hand, US colleagues are correct
claiming that mixes of allergens have shown effi-
cacy in daily practice for decades in their country.
In that sense the recommendations given by a
panel of experts on AIT clinical trials, addressing
crucial issues like this are of high value.63 One of
the fields they addressed was the design of a
study to compare the effectiveness and safety of
aeroallergen AIT by using one or a few allergens,
versus all or most allergens to which a patient is
sensitized. As it seems rather difficult to give
such a trial a double-blind placebo controlled
design, for trials in poly-allergic patients, we agree
with Bousquet et al there is a need for real-world
evidence of AIT efficacy that might be obtained
using the MASK-air App.64
AIT is such a complex treatment, because
allergen extracts of different composition interact
with the immune system of the allergic patient that
in turn is molded individually by the subject's ge-
netic background and past immunologic history.
As a result, patients respond each in their own way
to the doses administered during the course of an
AIT treatment, some tolerating higher doses from
the start, others needing slower up-dosing espe-
cially with SCIT, but also with SLIT. For some the
projected maintenance dose is just right, while for
others the maximum tolerated dose can be less
than a quarter of that even though their symptoms
are well-controlled. As a consequence, for some
clinician-researchers, the idea of making AIT a
pharmaceutical treatment and the concept of "one
tablet fits all" can be debatable for AIT. They
consider there is still room for the art of medicine
in the correct management of AIT. In the end, all
agree on one point: AIT is a prime example of
personalized medicine.Abbreviations
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